Article Information
History
- March 14, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Renske Altena1,2,*,
- Thuy A. Tran2,3,
- Una Kjällquist1,2,
- Mattias Karlsson4,
- Jonathan Siikanen3,
- Emma Jussing2,3,
- Antonios Tzortzakakis4,5,
- Olof Jonmarker5,6,
- Rimma Axelsson4,7 and
- Jonas Bergh1,2
- 1Medical Unit Breast, Endocrine Tumors and Sarcoma, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
- 2Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
- 3Department of Radiopharmacy, Karolinska University Hospital, Solna, Sweden
- 4Department of Medical Radiation Physics and Nuclear Medicine, Functional Unit of Nuclear Medicine, Karolinska University Hospital, Huddinge, Sweden
- 5Division of Radiology, Department for Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet
- 6Department of Radiology, Functional Unit of Medical Diagnostics, Karolinska University Hospital, Solna, Sweden
- 7Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
- ↵*Correspondence: Renske Altena MD PhD, Medical Unit Breast, Endocrine tumors and Sarcoma, Karolinska University Hospital Solna, Sweden, Email: renske.altena{at}ki.se, Telephone: +46 8 123 755 18
Posted March 14, 2023.
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II diagnostic imaging trial
